| EP3638243 | Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia | CELGENE | May 5, 2025 | WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB |
| EP3490582 | Methods And Compositions For Treating Myelofibrosis | ACCELERON PHARMA | Mar 10, 2025 | WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBB |
| EP3529360 | Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein Reduction | THE MEDICINES | Jan 15, 2025 | ZAKLADY FARMACEUTYCZNE POLPHARMA |
| EP3227447 | Guide Rna With Chemical Modifications | AGILENT | Jan 14, 2025 | WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBB |
| EP3226887 | Methods For Treating Myelodysplastic Syndromes And Sideroblastic Anemias | ACCELERON PHARMA | Dec 20, 2024 | WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBB |
| EP3460063 | Methods And Compositions For The Targeted Modification Of A Genome | REGENERON PHARMACEUTICALS | Dec 12, 2024 | WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBB |
| EP3380121 | Methods For Treating Eye Disorders | ACCELERON PHARMA | Sep 18, 2024 | WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB |
| EP3384049 | Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf | REGENERON PHARMACEUTICALS | Apr 24, 2024 | WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBB |
| EP3450562 | Method For Producing 2'-Fucosyllactose By Using Corynebacterium Glutamicum | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION | Apr 16, 2024 | WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBB |
| EP2967015 | Transgenic Mice Expressing Chimeric Major Histocompatibility Complex (Mhc) Class Ii Molecules | REGENERON PHARMACEUTICALS | Mar 5, 2024 | WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB |